Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 4
2005 8
2006 3
2007 6
2008 3
2009 1
2010 4
2011 2
2012 3
2013 10
2014 10
2015 10
2016 7
2017 10
2018 21
2019 18
2020 27
2021 15
2022 25
2023 21
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.
George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U; Erice ILD working group. George PM, et al. Among authors: vancheri c. Lancet Respir Med. 2020 Sep;8(9):925-934. doi: 10.1016/S2213-2600(20)30355-6. Lancet Respir Med. 2020. PMID: 32890499
Treatable traits in the NOVELTY study.
Agustí A, Rapsomaniki E, Beasley R, Hughes R, Müllerová H, Papi A, Pavord ID, van den Berge M, Faner R; NOVELTY Study Investigators. Agustí A, et al. Respirology. 2022 Nov;27(11):929-940. doi: 10.1111/resp.14325. Epub 2022 Jul 21. Respirology. 2022. PMID: 35861464 Free PMC article.
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS; ISABELA 1 and 2 Investigators. Maher TM, et al. JAMA. 2023 May 9;329(18):1567-1578. doi: 10.1001/jama.2023.5355. JAMA. 2023. PMID: 37159034 Free PMC article.
Rethinking Idiopathic Pulmonary Fibrosis.
Oldham JM, Vancheri C. Oldham JM, et al. Among authors: vancheri c. Clin Chest Med. 2021 Jun;42(2):263-273. doi: 10.1016/j.ccm.2021.03.005. Clin Chest Med. 2021. PMID: 34024402 Free PMC article. Review.
Validation of multidisciplinary diagnosis in IPF.
Castillo D, Walsh S, Hansell DM, Vasakova M, Cottin V, Altinisik G, Palmucci S, Sterclova M, Harari S, Richeldi L, Vancheri C, Wells AU; ERICE ILD working group. Castillo D, et al. Among authors: vancheri c. Lancet Respir Med. 2018 Feb;6(2):88-89. doi: 10.1016/S2213-2600(18)30023-7. Lancet Respir Med. 2018. PMID: 29413085 Review. No abstract available.
Comorbidities of IPF: How do they impact on prognosis.
Torrisi SE, Vancheri A, Pavone M, Sambataro G, Palmucci S, Vancheri C. Torrisi SE, et al. Among authors: vancheri c. Pulm Pharmacol Ther. 2018 Dec;53:6-11. doi: 10.1016/j.pupt.2018.09.003. Epub 2018 Sep 5. Pulm Pharmacol Ther. 2018. PMID: 30193867 Review.
196 results